Switching From Injectable Semaglutide to Oral Wegovy

Learn what the FDA label says about switching from Wegovy injections to oral Wegovy, including conversion limits, absorption, and administration.

WEIGHT MANAGEMENTTREATMENT OPTIONS

Sarina Helton, MSN, APRN, FNP-C, CAE-OM Founder, Optima Vida Healthcare

9/15/20269 min read

Switching From Injectable Semaglutide to Oral Wegovy: What the FDA Label Says

Some adults using injectable Wegovy may be able to transition to oral Wegovy. The formulations contain the same active drug, semaglutide, but they are not interchangeable milligram for milligram.

Current FDA prescribing information provides one specific direct conversion: an adult using Wegovy 2.4 mg once weekly for weight reduction or cardiovascular risk reduction may transition to Wegovy 25 mg once daily, with the tablet initiated one week after the final 2.4 mg injection.

That labeled conversion does not automatically apply to lower Wegovy doses, Wegovy HD 7.2 mg, Ozempic, compounded semaglutide, interrupted treatment, or another GLP-1 medication. Those situations require an individualized prescribing plan.

What Is Oral Wegovy?

Oral Wegovy is a once-daily tablet containing semaglutide, the same active drug found in injectable Wegovy.

It is FDA-approved, in combination with a reduced-calorie diet and increased physical activity, to:

Reduce excess body weight and maintain weight reduction in adults with obesity
Reduce excess body weight and maintain weight reduction in adults with overweight and at least one weight-related condition
Reduce the risk of major cardiovascular events in eligible adults with established cardiovascular disease and overweight or obesity

The injection delivers semaglutide under the skin once weekly. The tablet must pass through the stomach and be absorbed into the bloodstream. These different routes explain why the dose sizes and administration requirements differ. Read Oral Wegovy for Weight Loss for a complete overview of the tablet formulation.

What Does the FDA Label Say About Switching?

The FDA-approved direct switching instructions apply specifically to adults taking Wegovy 2.4 mg by weekly injection for weight reduction or cardiovascular risk reduction.

The prescribing information describes the transition as:

Discontinuation of the 2.4 mg weekly injection
Initiation of the 25 mg daily tablet one week later

This timing places the first tablet on the date the next weekly injection would otherwise have been due.

The label does not provide the same direct conversion for every injectable semaglutide dose or product. It also states that Wegovy is not recommended in combination with another semaglutide-containing product or another GLP-1 receptor agonist.

This section summarizes FDA labeling; it is not a self-directed switching schedule.

Why Is the Tablet 25 mg When the Injection Is 2.4 mg?

The milligram values cannot be compared directly because the formulations have very different absorption.

Oral Wegovy contains an absorption-enhancing ingredient called salcaprozate sodium, or SNAC. SNAC helps semaglutide survive in the stomach long enough for a small portion of the dose to be absorbed through the stomach lining.

Even with this technology, oral absorption is low and variable. A larger oral dose is therefore needed to produce systemic semaglutide exposure that may be comparable to a much smaller injected dose.

This does not mean that a 25 mg tablet is more than ten times as strong as a 2.4 mg injection. Milligram values are directly comparable only when the drug formulation, route, absorption, and bioavailability are equivalent.

What About Lower Wegovy Injection Doses?

The prescribing information provides a direct switch to the 25 mg tablet only from Wegovy 2.4 mg once weekly.

It does not establish a standard direct conversion from:

Wegovy 0.25 mg weekly
Wegovy 0.5 mg weekly
Wegovy 1 mg weekly
Wegovy 1.7 mg weekly
Wegovy HD 7.2 mg weekly

When a patient is using another injection dose, clinicians may consider treatment duration, side effects, previous dose tolerance, reason for switching, treatment interruptions, diabetes status, gastrointestinal symptoms, and the expected change in drug exposure.

A lower injectable dose cannot be assumed to correspond to the 25 mg oral maintenance dose. Because no labeled conversion exists, the prescriber must develop an individualized plan.

What Is the Labeled Oral Wegovy Escalation Schedule?

For adults beginning oral Wegovy rather than using the specific 2.4 mg injection-to-tablet conversion, the FDA label describes gradual escalation:

Days 1–30: 1.5 mg once daily
Days 31–60: 4 mg once daily
Days 61–90: 9 mg once daily
Day 91 onward: 25 mg once daily

The purpose of gradual escalation is to reduce gastrointestinal adverse reactions. The label permits delayed escalation when a dose is not tolerated.

This initiation schedule and the direct switch from Wegovy 2.4 mg injection are different labeled pathways. The appropriate pathway depends on the patient’s current product, dose, treatment history, and clinical circumstances. Increasing Your GLP-1 Dose explains why escalation and re-escalation decisions are based on tolerability rather than a rush to the highest dose.

Can Someone Transition From Ozempic to Oral Wegovy?

Potentially, but the FDA label does not provide a milligram-for-milligram conversion from Ozempic to oral Wegovy.

Ozempic is injectable semaglutide approved for type 2 diabetes and certain related risk-reduction indications. Its approved dosing and treatment goals differ from Wegovy’s weight-management indications.

A transition involving Ozempic may require consideration of:

Current Ozempic dose
Glucose control and A1c
Other diabetes medications
Risk of hypoglycemia
Weight-management goals
Insurance coverage
Expected variability in oral absorption

The Wegovy prescribing information notes that semaglutide exposure from the 25 mg tablet was lower in adults with type 2 diabetes than exposure from the 2.4 mg injection. It advises consideration of alternative treatment, including injectable Wegovy, when response to the tablet is inadequate in a patient with type 2 diabetes.

Can Someone Transition From Compounded Semaglutide?

A transition may be possible, but compounded semaglutide cannot be assumed to be equivalent to FDA-approved Wegovy injection.

Compounded products may differ in:

Concentration
Prescribed dose
Ingredients
Stability
Labeling and instructions
Form of semaglutide used
Accuracy of the administered dose

The number of syringe “units” does not identify the semaglutide dose unless the concentration is also known.

An accurate medication history may include the pharmacy label, concentration in milligrams per milliliter, prescribed dose in milligrams, volume injected, date of the last dose, treatment duration, side effects, and treatment response.

The FDA-approved direct conversion from Wegovy 2.4 mg injection to Wegovy 25 mg tablets does not automatically apply to compounded semaglutide. Read Compounded vs. FDA-Approved GLP-1 Medications for the regulatory and formulation differences.

What Does the Label Say About Oral Administration?

Oral Wegovy has specific administration requirements because food, beverages, water volume, and other medications can affect absorption.

The FDA prescribing information describes administration:

In the morning on an empty stomach
With no more than 4 ounces of plain water
With the tablet swallowed whole
With at least 30 minutes before food, beverages, or other oral medications

The tablet is not intended to be split, crushed, chewed, or dissolved.

Taking the tablet with food, another beverage, excessive water, or another oral medication may reduce semaglutide absorption. This daily fasting routine is one of the major practical differences between the tablet and the once-weekly injection.

This information summarizes the product label and does not replace individualized pharmacy or prescribing instructions.

What About Levothyroxine and Other Morning Medications?

Levothyroxine and oral Wegovy both have fasting-related administration requirements. Taking them together may affect absorption and create a scheduling conflict.

Other oral medications that require precise and consistent absorption may also need review, particularly drugs with a narrow therapeutic index.

Clinicians and pharmacists may adjust medication timing or monitoring based on the complete medication list. No single schedule is appropriate for every combination.

What Does the Label Say About a Missed Tablet?

The FDA label states that a missed oral Wegovy dose is skipped and that the next scheduled dose is taken the following day. The label does not recommend taking two tablets to replace a missed dose.

Because the tablet is designed for daily use, repeated missed doses can reduce treatment exposure. Daily adherence requirements may make the tablet more practical for some people and less practical for others.

Can Side Effects Return After the Transition?

Yes. A formulation change can be associated with renewed gastrointestinal symptoms even in someone who previously tolerated injectable semaglutide.

Possible adverse effects include:

Nausea
Vomiting
Diarrhea
Constipation
Reflux
Abdominal discomfort
Reduced appetite
Bloating or belching

Individual experience varies because oral absorption and drug exposure are variable. Related education is available in Most Common GLP-1 Side Effects

Severe or persistent abdominal pain, repeated vomiting, inability to maintain fluids, marked dehydration, fainting, very little urination, symptoms of a serious allergic reaction, severe pain radiating to the back, or right-upper-abdominal pain with fever or jaundice may indicate a complication requiring prompt in-person evaluation.

Does Oral Wegovy Work as Well as the Injection?

Oral Wegovy 25 mg produced clinically meaningful weight reduction in its clinical trial, but individual response varies.

In adults without type 2 diabetes, average semaglutide concentrations with the 25 mg tablet and 2.4 mg injection were similar, although exposure from the tablet was more variable.

In adults with type 2 diabetes, average semaglutide exposure was lower with the tablet than with the 2.4 mg injection. Oral Wegovy was not studied for weight reduction in adults with type 2 diabetes in the same way it was studied in adults without diabetes.

Clinical response may be assessed using weight trajectory, appetite, cravings, tolerability, adherence, glucose or A1c when relevant, ability to follow administration requirements, and overall health response.

Why Might the Tablet Be Preferred?

Reasons a patient may prefer oral Wegovy include:

A preference to avoid injections
Needle anxiety
Difficulty operating an injection pen
Frequent travel
Preference for tablet storage
Injection-site reactions
Ability to follow the fasting and timing routine consistently

Why Might the Injection Be Preferred?

Reasons a patient may prefer injectable Wegovy include:

Preference for once-weekly dosing
Multiple morning medications
Difficulty delaying food, beverages, or other medications
Difficulty remembering a daily medication
Preference for more predictable absorption
Previous benefit from the injection
Comfort with self-injection

Neither formulation is inherently best for everyone. Medical appropriateness, adherence, tolerability, lifestyle, access, and coverage all influence the decision. See How Are Anti-Obesity Medications Selected?.

How Can Insurance Affect the Transition?

Insurance coverage may differ between Wegovy tablets and Wegovy injection even though both contain semaglutide.

Coverage factors may include formulary placement, prior authorization, preferred formulation, diagnosis and BMI documentation, required pharmacy, existing authorization, and patient cost-sharing.

Confirming access before a formulation change can help prevent an unintended interruption, but coverage policies and manufacturer programs can change.

What Information May Be Reviewed Before a Transition?

A clinical review may include:

Current semaglutide product and dose
Date of the last dose
Treatment duration and interruptions
Weight trajectory and response
Side effects
Diabetes status and glucose-lowering medications
Kidney function when relevant
Gastrointestinal symptoms
Pregnancy-related considerations
Morning medications
Ability to follow fasting requirements
Insurance coverage
Reason for changing formulations

An extended interruption may alter tolerability and may require a different plan from a continuous transition.

Can a Patient Transition Back to the Injection?

Yes. The Wegovy prescribing information also provides a labeled transition from the 25 mg tablet to injection.

For adults using the 25 mg tablet, the label describes initiation of the 2.4 mg weekly injection the day after the last 25 mg tablet. When the 25 mg tablet is not tolerated, the label permits consideration of the 1.7 mg weekly injection.

For adults with type 2 diabetes who need additional weight reduction, the label describes consideration of the 1.7 mg injection followed by the recommended injection escalation schedule.

These instructions apply to specific Wegovy formulations and circumstances. They are not universal conversions for other semaglutide products.

Frequently Asked Questions

Can Wegovy 2.4 mg Injection Be Switched Directly to Oral Wegovy?

The FDA label provides a specific transition from Wegovy 2.4 mg once weekly to Wegovy 25 mg once daily, with the tablet initiated one week after the final injection. This is a label summary, not an individualized switching instruction.

Is There a Conversion From Wegovy 1.7 mg to Oral Wegovy?

The current label does not provide the same direct conversion from Wegovy 1.7 mg or lower injection strengths to the 25 mg tablet.

Can Ozempic Be Converted Directly to Oral Wegovy?

The Wegovy label does not provide a standard milligram-for-milligram conversion from Ozempic to oral Wegovy. The products have different labeled indications, doses, and treatment considerations.

Is Oral Wegovy 25 mg Stronger Than Wegovy 2.4 mg Injection?

The numbers cannot be compared directly. Oral semaglutide has low and variable absorption, while injected semaglutide enters systemic circulation through a different route.

Can Injectable and Oral Wegovy Be Used Together During a Transition?

The FDA label does not recommend Wegovy tablets or injections with another semaglutide-containing product or another GLP-1 receptor agonist. Learn more in Can GLP-1 Medications Be Combined?.

The Bottom Line

Some adults can transition from injectable semaglutide to oral Wegovy, but the appropriate plan depends on the exact product, dose, treatment history, clinical response, and reason for changing formulations.

The clearest FDA-labeled conversion is from Wegovy 2.4 mg injection once weekly to Wegovy 25 mg tablet once daily, with the tablet initiated one week after the final injection.

The label does not provide a universal conversion for lower Wegovy injection doses, Wegovy HD 7.2 mg, Ozempic, compounded semaglutide, prolonged treatment interruptions, or other GLP-1 medications.

Oral Wegovy also has strict daily administration requirements that do not apply to the injection. These practical differences, along with tolerability, diabetes status, medication schedule, adherence, access, and insurance coverage, help determine whether a transition is appropriate.

Written by and clinically reviewed for accuracy by:

Sarina Helton, MSN, APRN, FNP-C, CAE-OM

Sarina Helton, MSN, APRN, FNP-C, CAE-OM, is a board-certified family nurse practitioner and founder of Optima Vida Healthcare. Her clinical focus includes obesity medicine, medical weight management, metabolic health, hormone-related concerns, sexual health, hair loss, and evidence-based telehealth care.

Last medically reviewed: September 3, 2026

Learn More About Medical Weight Management

At Optima Vida Healthcare (OVH), weight-management care is individualized according to medical history, previous treatment, medication response, side effects, goals, and long-term needs.

Treatment may include GLP-1 or other weight-management medications when clinically appropriate, along with ongoing monitoring and support.

Start a Weight-Management Evaluation →

Visit ovhmed.com for more information →

Prescription medication is not guaranteed. Prescribing decisions are made by a licensed healthcare professional after an appropriate clinical evaluation.

Educational Disclaimer

This article is provided for general educational purposes only. It summarizes FDA prescribing information but does not provide individualized medical advice, prescribe a switching schedule, recommend a medication change, or replace instructions from a licensed prescriber or pharmacist.

Sources

U.S. Food and Drug Administration. Wegovy Prescribing Information. Revised February 2026. FDA label
U.S. Food and Drug Administration. FDA Approves Higher-Dose Semaglutide. March 19, 2026. FDA announcement
Novo Nordisk. Current Wegovy Prescribing Information. Manufacturer label

Switching From Injectable Semaglutide to Oral Wegovy
Learn what the FDA label says about switching from Wegovy injections to oral Wegovy, including conversion limits, absorption, and administration.
switch-injectable-semaglutide-to-oral-wegovy
switch from injectable semaglutide to oral Wegovy
Wegovy injection to pill, oral Wegovy conversion, switch from Ozempic to oral Wegovy, Wegovy tablet dosing, injectable vs. oral semaglutide
Some adults can transition from Wegovy 2.4 mg injections to oral Wegovy 25 mg, but the FDA-labeled conversion does not apply to every semaglutide product or dose.